HBV RNA Destabilizer

Novel small molecule RNA destabilizers employ a unique mechanism to specifically destabilize HBV RNA transcripts leading to reductions in HBV proteins, including HBsAg, in preclinical models.


Arbutus has identified several small molecule HBV RNA destabilizers, exemplified by AB-452. These therapeutics are expected to be orally available with the potential to be used in combination regimens to deliver a cure for chronic HBV. These molecules have shown complementary effects when combined with Arbutus’ HBV RNAi agents in vitro. Arbutus remains committed to the RNA destabilizer space and continues to further characterize AB-452 and conduct preclinical development of next-generation RNA destabilizer anti-HBV agents.